Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis

[1]  E. H. P. van Dijkhuizen,et al.  MTX intolerance in children and adolescents with juvenile idiopathic arthritis. , 2020, Rheumatology.

[2]  D. Foell,et al.  Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Long‐Term Safety Data from the German BIKER Registry , 2019, ACR open rheumatology.

[3]  K. Minden,et al.  Time of Disease‐Modifying Antirheumatic Drug Start in Juvenile Idiopathic Arthritis and the Likelihood of a Drug‐Free Remission in Young Adulthood , 2019, Arthritis care & research.

[4]  K. Raza,et al.  Window of opportunity in rheumatoid arthritis – definitions and supporting evidence: from old to new perspectives , 2019, RMD Open.

[5]  Bin Huang,et al.  Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti–Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease , 2018, Arthritis & rheumatology.

[6]  L. Rodríguez-Rodríguez,et al.  Are rheumatologists adhering to the concepts window of opportunity and treat-to-target? Earlier and more intense disease-modifying anti-rheumatic drug treatment over time in patients with early arthritis in the PEARL study. , 2018, Clinical and experimental rheumatology.

[7]  Marcus John Beasley,et al.  Flares After Withdrawal of Biologic Therapies in Juvenile Idiopathic Arthritis: Clinical and Laboratory Correlates of Remission Duration , 2018, Arthritis care & research.

[8]  D. Foell,et al.  Treating juvenile idiopathic arthritis to target: recommendations of an international task force , 2018, Annals of the rheumatic diseases.

[9]  K. Minden,et al.  Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA , 2018, Annals of the rheumatic diseases.

[10]  N. Wulffraat,et al.  Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis , 2017, Annals of the rheumatic diseases.

[11]  I. Foeldvari,et al.  Protocols on classification, monitoring and therapy in children’s rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis , 2017, Pediatric Rheumatology.

[12]  S. Ringold,et al.  Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance , 2017, Journal of Rheumatology.

[13]  C. Allaart,et al.  A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study , 2017, Pediatric Rheumatology.

[14]  K. Minden,et al.  Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab , 2016, Arthritis Research & Therapy.

[15]  G. Horneff,et al.  Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis , 2016, Clinical Rheumatology.

[16]  D. Symmons,et al.  Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis , 2016, RMD Open.

[17]  K. Minden,et al.  OP0219 Update on Malignancies in Children with Juvenile Idiopathic Arthritis in The German Biker Registry , 2016, Clinical and experimental rheumatology.

[18]  T. Southwood,et al.  Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study , 2015, Rheumatology.

[19]  E. Haddad,et al.  The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort , 2015, Pediatric Rheumatology.

[20]  A. Reiff,et al.  Impact of Medication Withdrawal Method on Flare‐Free Survival in Patients with Juvenile Idiopathic Arthritis on Combination Therapy , 2015, Arthritis care & research.

[21]  I. Becker,et al.  Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 2 years , 2015, Rheumatology International.

[22]  A. Filer,et al.  The therapeutic window of opportunity in rheumatoid arthritis: does it ever close? , 2015, Annals of the rheumatic diseases.

[23]  A. Martini,et al.  Defining Criteria for Disease Activity States in Nonsystemic Juvenile Idiopathic Arthritis Based on a Three‐Variable Juvenile Arthritis Disease Activity Score , 2014, Arthritis care & research.

[24]  K. Minden,et al.  Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA) , 2014, Annals of the rheumatic diseases.

[25]  P. Nigrovic,et al.  2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. , 2013, Arthritis and rheumatism.

[26]  I. Becker,et al.  Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis , 2013, Clinical Rheumatology.

[27]  J. Schoones,et al.  What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review , 2013, Annals of the rheumatic diseases.

[28]  K. Minden,et al.  Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. , 2012, Rheumatology.

[29]  V. Opoka-Winiarska,et al.  Clinical remission in juvenile idiopathic arthritis after termination of etanercept , 2012, Rheumatology International.

[30]  E. Hoppenreijs,et al.  Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. , 2011, JAMA.

[31]  A. King,et al.  Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: a twelve-year experience. , 2011, Arthritis and rheumatism.

[32]  S. Kamphuis,et al.  High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. , 2011, Arthritis and rheumatism.

[33]  J. Gerss,et al.  Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. , 2010, JAMA.

[34]  S. Kamphuis,et al.  Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register , 2009, Annals of the rheumatic diseases.

[35]  I. Foeldvari,et al.  Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry , 2008, Annals of the rheumatic diseases.

[36]  B. Prakken,et al.  Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study. , 2007, Clinical and experimental rheumatology.

[37]  R. Petty,et al.  Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. , 2004, The Journal of rheumatology.

[38]  E. Giannini,et al.  Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. , 2004, The Journal of rheumatology.

[39]  M. Suarez‐Almazor,et al.  International League of Associations for Rheumatology: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001 , 2004 .

[40]  K. Minden,et al.  The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). , 2001, Clinical and experimental rheumatology.

[41]  J. Robins,et al.  Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments , 2001 .

[42]  A. Reiff,et al.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. , 2000, The New England journal of medicine.

[43]  M. Suarez‐Almazor,et al.  Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. , 1998, The Journal of rheumatology.

[44]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[45]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[46]  J. Fries,et al.  The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. , 2003, The Journal of rheumatology.

[47]  R. Schneider,et al.  Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. , 2003, Arthritis and rheumatism.